FDA and MoCRA Compliance for Cosmetics
Marketing a cosmetic in the United States requires compliance with the FDA's wider regulatory framework and the duties introduced by the Modernization of Cosmetics Regulation Act of 2022, known as MoCRA.
Product classification, operator identity and consistent data form the foundation of the process.
SHAPYPRO brings these requirements together in one strategy covering registrations, listings, safety documentation, labelling and post-market procedures.
One Compliance Framework for FDA and MoCRA
The FDA regulates cosmetics under the Federal Food, Drug, and Cosmetic Act and other applicable provisions. MoCRA amended that framework and expanded both industry duties and FDA authority.
FDA compliance and MoCRA compliance should therefore be treated as one service instead of two separate projects. MoCRA forms part of the legal framework that applies to cosmetics marketed in the United States.
The review begins with the product's identity and intended use. Claims to treat or prevent disease, or to affect the structure or function of the body, may cause a product to be regulated as a drug or as both a cosmetic and a drug.
That classification changes the regulatory pathway and must be resolved before registrations are prepared, information is submitted or labelling is finalised.
Key MoCRA Requirements
MoCRA introduces duties affecting facilities, products, safety evidence, labelling and post-market oversight.
Their application depends on each company's role and any available exemptions.
Facility Registration
Facilities that manufacture or process cosmetics distributed in the United States must register with the FDA unless an exemption applies.
Registration is renewed every two years, and foreign facilities must designate a US agent.
Product Listing
The Responsible Person must list each marketed cosmetic product and provide the required product and ingredient information.
Product listings must be updated annually and when certain specified changes occur.
Safety Substantiation
The Responsible Person must ensure and maintain records supporting adequate safety substantiation.
MoCRA does not prescribe one test for every product. The evidence must be scientifically sound and appropriate to the formula and intended use.
Serious Adverse Events
Serious adverse events associated with a cosmetic must be reported to the FDA within 15 business days of receipt.
Additional information received during the following year may require an update within the same period.
Labelling and Contact Channel
The label must comply with general FDA rules and include a domestic address, domestic telephone number or electronic contact information through which the Responsible Person can receive adverse-event reports.
Records and FDA Authority
Companies need procedures that allow relevant records to be retained and retrieved.
MoCRA gave the FDA new authority to access certain records and order a mandatory recall when the statutory conditions are met.
Roles and Responsibilities
Accurate registration and listing depend on each operator understanding its role. SHAPYPRO confirms responsibilities and gathers consistent information before submissions are prepared.
Responsible Person
This is the manufacturer, packer or distributor whose name appears on the label.
The role carries key duties for product listing, safety substantiation and adverse-event management.
Manufacturing or Processing Facility
The facility must determine whether registration applies, keep its information current and coordinate the identifiers and data used in product listings.
US Agent
A registered foreign facility must designate a US agent who acts as a contact point with the FDA for communications concerning the registration.
A Technical File with Consistent Data
The process does not end when a form is submitted. The product name, formula, categories, facility, Responsible Person and label information must agree.
A commercial or technical change may require an update and may also affect safety substantiation.
SHAPYPRO prepares a documentary foundation connecting the formula, specifications, manufacturing, microbiological controls, stability, safety and claims.
This structure supports the initial submission, annual updates and responses to an FDA question or inspection.
Small Business Exemptions and Developing Requirements
The obligations do not apply in the same way to every business. Before relying on an exemption or planning for a developing requirement, the current legal criteria should be checked and the decision documented.
Exemptions for Certain Small Businesses
MoCRA provides exemptions from good manufacturing practice, facility registration and product listing for certain small businesses.
These are not blanket exemptions. Eligibility depends on the statutory criteria and does not extend to specified categories, including products that regularly contact the eye's mucous membrane, injected products, products intended for internal use and products intended to alter appearance for more than 24 hours when consumer removal is not part of the customary conditions of use.
Eligibility should be documented before an obligation is treated as not applicable.
Requirements Under Development
MoCRA also requires the FDA to establish regulations for cosmetic good manufacturing practice and fragrance allergen labelling and to address methods for detecting asbestos in talc-containing cosmetic products.
While these regulatory processes continue, businesses must distinguish current obligations from future rules and monitor official updates.
How SHAPYPRO Supports Compliance
SHAPYPRO treats compliance as one coordinated project so that classification, registrations, safety, labelling and post-market procedures use consistent information.
Classification and Claims
We review product function, presentation and claims to confirm whether the cosmetic pathway applies or whether the product may also be regulated as a drug.
Registration and Listing
We organise facility and product information, check it for consistency and support preparation of the relevant submissions.
Safety and Labelling
We connect safety evidence with the formula and check the label elements that affect compliance and adverse-event reporting.
Post-Market Procedures
We help define how adverse events are received, assessed, documented and escalated, together with change and update controls.
The scope is adapted to the company's actual role. A brand, foreign facility, contract manufacturer and distributor do not always have the same duties or require the same level of support.
Working Methodology
Classification
We review the product, intended use and claims before defining the compliance route.
Operator Map
We identify facilities, the Responsible Person, US agent and contractual responsibilities.
Gap Review
We compare the formula, safety evidence, labelling and existing records with the applicable obligations.
Data Preparation
We structure and verify the information required for registrations, listings and internal procedures.
Maintenance
We plan renewals, annual updates, change management and regulatory monitoring.
Frequently Asked Questions About FDA and MoCRA
Are FDA Compliance and MoCRA Compliance Separate Services?
No. MoCRA forms part of the legal framework that the FDA applies to cosmetics. The page and project should address them together, beginning with general classification and then covering the specific MoCRA duties.
Does the FDA Approve Cosmetics Before Sale?
As a general rule, the FDA does not pre-approve cosmetic products or their ingredients, apart from the applicable requirements for certain colour additives.
The company remains responsible for product safety and proper labelling.
Must Every Business Register Facilities and List Products?
Not in every case. Statutory exclusions and exemptions exist, including some for small businesses.
They must be assessed using the actual details of the company, facility and product category.
How Often Is Information Updated?
Facility registration is renewed every two years. Product listings are updated annually and must also reflect specified changes where applicable.
Is an EU Product File Sufficient for the United States?
It can provide useful information, particularly for safety, but it does not replace a US review.
Classification, labelling, operator roles and FDA submissions require specific adaptation.
One Plan for FDA and MoCRA
Share the product, formula, label, facilities involved and launch schedule with SHAPYPRO.
We will prepare one roadmap covering FDA and MoCRA duties without duplicating work or documentation.
